ERBB2 and breast cancer: CPT1A mRNA levels are lower in slowly-proliferating HER2-positive and luminal B breast cancer subtypes than in highly proliferating and metastatic TNBC [128], suggesting that in breast cancer FAO is active more in indolent and slow progressing subtypes.